Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1987 1
1989 1
1990 3
1991 2
1992 2
1993 2
1995 1
1996 3
1998 4
1999 2
2000 1
2001 1
2002 1
2003 2
2004 1
2005 1
2006 4
2007 2
2008 4
2009 4
2010 3
2011 4
2012 7
2013 8
2014 5
2015 6
2016 4
2017 3
2018 3
2019 1
2020 7
2021 4
2022 7
2023 4
2024 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 10
Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.
Davis RE, Greenberg PL. Davis RE, et al. Among authors: greenberg pl. Leuk Res. 1998 Sep;22(9):767-77. doi: 10.1016/s0145-2126(98)00051-4. Leuk Res. 1998. PMID: 9716007 Free article.
To investigate whether bcl-2 plays a role in the increase of myeloblasts in myelodysplastic syndromes (MDS) and their progression to acute myeloid leukemia (AML), we studied bcl-2 expression in initial (pre-therapy) bone marrow biopsies from MDS at early (refractory …
To investigate whether bcl-2 plays a role in the increase of myeloblasts in myelodysplastic syndromes (MDS) and their progress …
Risk factors and their relationship to prognosis in myelodysplastic syndromes.
Greenberg PL. Greenberg PL. Leuk Res. 1998 May;22 Suppl 1:S3-6. doi: 10.1016/s0145-2126(98)00040-x. Leuk Res. 1998. PMID: 9734692 Review.
Recent efforts have been directed at improving the methodology for predicting clinical outcomes in patients with myelodysplastic syndromes (MDS). This review focuses on the development of a consensual, prognostic, risk-based analysis system generated by the Internat …
Recent efforts have been directed at improving the methodology for predicting clinical outcomes in patients with myelodysplastic s …
Prognostic factors and scoring systems in myelodysplastic syndromes.
Sanz GF, Sanz MA, Greenberg PL. Sanz GF, et al. Among authors: greenberg pl. Haematologica. 1998 Apr;83(4):358-68. Haematologica. 1998. PMID: 9592987 Review.
BACKGROUND AND OBJECTIVE: Great prognostic heterogeneity complicates therapy-planning and a correct evaluation of clinical trials in myelodysplastic syndromes (MDS). Thus, the development of a prognostic classification of MDS is of major clinical relevance, especial …
BACKGROUND AND OBJECTIVE: Great prognostic heterogeneity complicates therapy-planning and a correct evaluation of clinical trials in myel …
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Rajapaksa R, et al. Among authors: greenberg pl. Blood. 1996 Dec 1;88(11):4275-87. Blood. 1996. PMID: 8943864 Free article.
Ineffective hematopoiesis with associated cytopenias and potential evolution to acute myeloid leukemia (AML) characterize patients with myelodysplastic syndrome (MDS). We evaluated levels of apoptosis and of apoptosis-related oncoproteins (c-Myc, which enhances, and Bcl-2, …
Ineffective hematopoiesis with associated cytopenias and potential evolution to acute myeloid leukemia (AML) characterize patients with m …
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL. Negrin RS, et al. Among authors: greenberg pl. Blood. 1996 May 15;87(10):4076-81. Blood. 1996. PMID: 8639764 Free article. Clinical Trial.
Patients with myelodysplastic syndromes (MDS) have refractory cytopenias leading to transfusion requirements and infectious complications. ...
Patients with myelodysplastic syndromes (MDS) have refractory cytopenias leading to transfusion requirements and infectious co …
Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes.
Nagler A, MacKichan ML, Negrin RS, Donlon T, Greenberg PL. Nagler A, et al. Among authors: greenberg pl. Leukemia. 1995 Jan;9(1):30-9. Leukemia. 1995. PMID: 7531261
We evaluated the effects of 2 months of G-CSF treatment on in vitro hematopoiesis in 17 patients with myelodysplastic syndromes (MDS). Although in vitro marrow myeloid progenitor cell (CFU-GM) growth stimulated by G-CSF generally remained subnormal, in the majority …
We evaluated the effects of 2 months of G-CSF treatment on in vitro hematopoiesis in 17 patients with myelodysplastic syndromes …
Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. Negrin RS, et al. Among authors: greenberg pl. Blood. 1993 Aug 1;82(3):737-43. Blood. 1993. PMID: 7687889 Free article. Clinical Trial.
We treated myelodysplastic syndrome patients (MDS) with both recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin (EPO) to determine whether such combination therapy resulted in improvement of their anemias. ...
We treated myelodysplastic syndrome patients (MDS) with both recombinant human granulocyte colony-stimulating factor (G-CSF) and reco …
111 results